Compare Affirm Holdings Inc (AFRM) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Affirm Holdings Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Affirm Holdings Inc trades at $80.4 (market cap $28.00B), while Ginkgo Bioworks Holdings Inc trades at $8.87 (market cap $610.13M). The key difference: Affirm Holdings Inc is far larger — about 45.9× Ginkgo Bioworks Holdings Inc's market cap, and Affirm Holdings Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AFRM | DNA | |
|---|---|---|
Market Cap | $28.00B | $610.13M |
Sector | Financials | Health |
52-Week High | $92.18 | $16.14 |
52-Week Low | $42.53 | $5.48 |
Enterprise Value | $34.61B | $647.37M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFRM trades at $83.62, down 1.14% on the day, with a bullish technical outlook supported by moving averages and a golden cross pattern. The company reported strong revenue growth, reaching $3.22 billion in 2025, and has consistently beaten earnings expectations in recent quarters. Recent partnerships with Bed Bath & Beyond and Backcountry expand its merchant network, driving transaction volume growth.
The outlook remains positive with analyst consensus favoring a buy rating and a $89 price target, though high valuation multiples and overbought RSI levels pose near-term risks. Earnings growth and BNPL market expansion are key catalysts, while credit losses and competition represent ongoing challenges for shareholders.
DNA trades at $10.11, down 2.79% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $312.76M on $170.16M revenue in 2025, with negative cash flow and declining revenue projected into 2026. Recent news highlights include Ginkgo Bioworks' pivot to autonomous labs and insider selling activity, while analyst consensus shows a divided outlook with 45% buy ratings.
The outlook remains challenging due to persistent losses and cash burn, though technical strength offers short-term support. Investment opportunity hinges on successful execution of the autonomous lab strategy, while risks include continued negative margins, high cash consumption, and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
